Special Issue

Metabolic Disorders in Chronic Obstructive Pulmonary Disease and Atherosclerosis

Message from the Guest Editors

A growing amount of evidence suggests an immune and metabolic axis that links COPD and atherosclerosis in their comorbid development and courses. Lipid metabolism is part of this axis, and its disorders are one of the most important links in the complex chain of processes underlying the pathogenesis of both COPD and atherosclerosis. Indeed, the lungs have a unique lipid biology, disturbances of which can be caused by smoking. The development of the lipid theory of atherogenesis has expanded the understanding of the role of lipids from a simple morphological substrate of atherosclerotic deposits to a participant of many immune processes, the disorders of which are part of the pathogenesis of atherosclerosis. It should be noted that the keys to understanding many links in the pathogenesis of both the isolated and comorbid course of COPD and atherosclerosis are still largely unknown to clinicians and researchers. Thus, this Special Issue focuses on original research and thorough reviews of recent advances in the metabolic and immune mechanisms underlying COPD and atherosclerosis

Guest Editors

Dr. Stanislav Kotlyarov Department of Nursing, Ryazan State Medical University, Ryazan, Russia

Dr. Xiaoyan Zhang Health Science Center, East China Normal University, Shanghai 200241, China

Deadline for manuscript submissions

closed (15 September 2023)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 5.7 Indexed in PubMed



mdpi.com/si/160709

Metabolites MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 5.7 Indexed in PubMed



metabolites



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

 Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy
Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 13.9 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2024).